Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 18 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

The 50-day moving average has crossed above the 200-day moving average for Sandu Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the stock’s recent price action and a mixed technical backdrop suggest this signal warrants a cautious interpretation rather than an outright bullish endorsement.

Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 June 2026, reflecting notable improvements in its technical outlook and valuation metrics despite ongoing fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 37.0, signalling a cautious but more optimistic stance among analysts.

Sandu Pharmaceuticals Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 26 May 2026, reflecting a complex interplay of valuation improvements offset by deteriorating financial trends and weak quality metrics. Despite an attractive valuation profile, the company’s long-term fundamentals and technical outlook remain concerning, prompting a cautious stance from analysts.

Sandu Pharmaceuticals Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging market backdrop and a recent upgrade to a Strong Sell Mojo Grade. This article analyses the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical averages and peer benchmarks, providing a comprehensive view of its price attractiveness and investment potential.

Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in its valuation metrics despite ongoing challenges in financial performance and technical indicators. This nuanced shift reflects a more attractive entry point for investors, even as the company continues to face headwinds in growth and profitability.

Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to a very attractive rating despite recent share price declines and a challenging market backdrop. This article analyses the company’s updated price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical levels and peer benchmarks, providing investors with a comprehensive view of its current price attractiveness.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sandu Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from fair to expensive territory, raising questions about its price attractiveness relative to historical levels and peer benchmarks. Despite recent gains in share price, the company’s micro-cap status and deteriorating mojo grade to a strong sell underscore investor caution amid stretched multiples.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Sep 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 0.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment, raising questions about its price attractiveness relative to historical and peer benchmarks.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This change, driven primarily by improvements in price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

A sharp decline over the past two sessions has dragged Sandu Pharmaceuticals Ltd to a fresh 52-week low of Rs 30 on 30 Mar 2026, marking a significant 49% drop from its peak of Rs 58.8 within the last year. This downturn comes despite some pockets of financial improvement, highlighting a complex interplay of market sentiment and company fundamentals.